Incyte (INCY) PT Bumped to $115 at Leerink as Gilead's (GILD) Momelotinib Disappoints

November 17, 2016 8:12 AM EST
Get Alerts INCY Hot Sheet
Price: $100.63 -2.19%

Rating Summary:
    21 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade INCY Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and bumped his price target on Incyte (NASDAQ: INCY) to $115.00 (from $101.00) as Gilead Sciences' (NASDAQ: GILD) momelotinib disappoints.

Schmidt commented, "Today GILD (MP) reported top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis (MF): SIMPLIFY-1 and SIMPLIFY-II. Results from both trials are disappointing, in our view making it highly unlikely that GILD would be able to obtain regulatory approval. Removal of this uncertainty on the revenue outlook of INCY's key commercial product (see our recent deep-dive here: LINK), combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. While we assumed only a modest success probability for momelotinib, our prior scenario analysis suggested 7-22% downside potential to INCY's valuation in a rage of momelotinib success scenarios. Raising our PT to $115 (from $101)."

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $100.74 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Definitive Agreement

Add Your Comment